cd19 car t-cell mechanism
Transforms Chronic Disease Management By 2027
In 2024 the CASTLE trial reported a 73% reduction in corticosteroid use within six weeks, showing that a single CD19 CAR-T infusion can sustain B-cell aplasia for up to 18 months and offer a new way to manage refractory autoimmunity. This breakthrough suggests that by 2027 chronic disease treatment could